KW 027
Alternative Names: KW-027Latest Information Update: 06 Nov 2023
At a glance
- Originator Beijing Kawin Technology Share-Holding
- Class Antibodies; Antivirals; Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hepatitis B
Most Recent Events
- 06 Sep 2023 Phase-I clinical trials in Hepatitis in China (Parenteral), prior to September 2023 (Beijing kawin technology share holding pipeline, September 2023)
- 06 Sep 2023 Center for Drug Evaluation (CDE ) of the State Drug Administration approves clinical trial application for KW 027 in Hepatitis B, prior to September 2023 (Beijing kawin technology share holding pipeline, September 2023)